TECH

Bio-Techne Corporation

Fundamental data last updated:August 9, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

 


VALUATION

P/E

73.57

Market Cap ($M USD)

$8.10B

Forward P/E

19.44

PEG

0.07

PRICE TO SALES

6.69

PRICE TO BOOK

3.87

EV / EBITDA

31.57

5-Year Average P/E

Free Cash Flow Yield

3.33%

DCF Value

$22.45

Graham Number

$14.54

Price to FCF

30.03

EV to FCF

30.33

Earnings Yield

1.36%

FCF Yield

3.33%

DIVIDEND

Yield

0.62%

Annual Payout

$0.32

Payout Ratio

45.47%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.70

Next Year EPS Growth Estimate

$2.66

Next Year Revenue Growth Estimate

$1.56B

Return on Equity (ROE)

5.49%

FREE CASH FLOW

Operating Margin

12.70%

Debt-to-Equity

0.23

Piotroski F-Score

8

Altman Z-Score

11.14

Return on Invested Capital (ROIC)

6.41%

Current Ratio

4.49

Quick Ratio

3.18

Net Debt to EBITDA

0.31

Interest Coverage

14.64

Gross Profit margin

64.96%

FCF PER SHARE

$1.73

REVENUE PER SHARE

$7.77

Gainseekers Quantitative Analysis

Summary

Bio-Techne Corporation’s valuation paints a complex picture. Despite a staggering Forward P/E of 15.35, the stock traded well below its DCF Value, suggesting potential undervaluation. The Altman Z-score of 11.32 indicates robust financial health, while a minuscule Earnings Yield of 1.45% raises questions about immediate returns. The market’s pricing seems to overlook the Graham Number, hinting at a disconnect between intrinsic value and market perception. This discrepancy, coupled with a high Price/Earnings ratio, suggests the stock might be priced for perfection, yet its fundamentals offer a cushion against volatility.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Bio-Techne is strategically positioned to leverage AI advancements. The industry's inherent demand for innovation aligns with AI-driven efficiencies, offering potential for enhanced research and development processes. This alignment could bolster the company's adaptability and competitive edge in a rapidly evolving tech landscape.

The Bull Case

For the discerning GARP investor, Bio-Techne offers compelling reasons to buy. A Piotroski F-Score of 8 signals strong financial health, while a ROIC of 6.41% reflects efficient capital use. The company's robust operating margin of 12.7% and a healthy FCF Yield, despite being low, indicate potential for growth and profitability. These metrics suggest a company with pricing power and operational efficiency, making it an attractive proposition for those seeking value with growth potential.

The Bear Case

However, the bear case cannot be ignored. The Price/Sales ratio of 6.25 and Price/Book of 3.62 highlight significant valuation concerns. The stock's distance from its 52-week high suggests technical overextension, while a low Earnings Yield questions its immediate attractiveness. Despite a safe Debt/Equity ratio, these valuation multiples could deter investors wary of overpaying for growth.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$60.33

Institutional Ownership %

1-Year Beta

1.41

Insider Buying % (6 Mo)

Distance to 52-Week High

39.55%

Distance to 52-Week Low

16.46%

EARNINGS SURPRISE %

-3.64%

50-DAY SMA

$52.24

200-DAY SMA

$57.58

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.